{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:16:09Z","timestamp":1791357369566,"version":"4.3.1"},"reference-count":23,"publisher":"Hindawi Limited","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1761,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1111\/j.1365-2710.2010.01219.x","type":"journal-article","created":{"date-parts":[[2010,11,7]],"date-time":"2010-11-07T10:43:38Z","timestamp":1289126618000},"page":"651-663","source":"Crossref","is-referenced-by-count":7,"title":["Explicit review of risperidone long-acting injection prescribing practice"],"prefix":"10.1155","volume":"36","author":[{"given":"A.","family":"Wheeler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Vanderpyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Carswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Stojkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2010,11,5]]},"reference":[{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1440-1614.2005.01516.x","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders","volume":"39","author":"Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Schizophrenia and Related Disorders","year":"2005","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB2|cit2","first-page":"7S","article-title":"Clinical Practice Guidelines: treatment of schizophrenia","volume":"50","author":"Canadian Psychiatric Association","year":"2005","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/oxfordjournals.schbul.a007071","article-title":"The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003","volume":"30","author":"Lehman","year":"2004","journal-title":"Schizophrenia Bulletin"},{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"500","DOI":"10.4088\/JCP.v65n0408","article-title":"The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update","volume":"65","author":"Miller","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB5|cit5","first-page":"2","article-title":"The expert consensus guideline series optimizing pharmacologic treatment of psychotic disorders","volume":"64","author":"Expert Consensus Panel","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB6|cit6","volume-title":"Schizophrenia: Core Interventions in the Treatment of Schizophrenia in Primary and Secondary Care. Clinical Guideline 1","author":"National Collaborating Centre for Mental Health","year":"2002"},{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB7|cit7","volume-title":"Practice Guideline for the Treatment of Patients with Schizophrenia","author":"American Psychiatric Association","year":"2004"},{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.euroneuro.2004.07.003","article-title":"Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets","volume":"15","author":"Chue","year":"2005","journal-title":"European Neuropsychopharmacology"},{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","article-title":"Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic","volume":"160","author":"Kane","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB10|cit10","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004161","article-title":"Depot risperidone for schizophrenia","volume":"4","author":"Hosalli","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1192\/bjp.bp.105.017020","article-title":"Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder randomised, controlled, open-label study","volume":"191","author":"Keks","year":"2007","journal-title":"British Journal of Psychiatry"},{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.4088\/JCP.v64n1017","article-title":"Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic","volume":"64","author":"Fleischhacker","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB13|cit13","volume-title":"Data Sheet: Risperdal Consta\u2122","author":"Janssen-Cilag (New Zealand) Ltd","year":"2009"},{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB14|cit14","volume-title":"New Zealand Pharmaceutical Schedule - August 2009","author":"Pharmaceutical Management Agency (PHARMAC)","year":"2009"},{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB15|cit15","volume-title":"Toward Clinical Excellence; an Introduction to Clinical Audit, Peer Review and Other Clinical Practice Improvement Activities","author":"Ministry of Health","year":"2002"},{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB16|cit16","volume-title":"2006 Census: District Health Board Area Summary Tables","author":"Statistics New Zealand","year":"2006"},{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2165\/11537680-000000000-00000","article-title":"Comparative effectiveness of long-acting risperidone: a report of resource utilisation and costs in a 12-month mirror-image analysis","volume":"30","author":"Carswell","year":"2010","journal-title":"Clinical Drug Investigation"},{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB18|cit18","volume-title":"A Users Guide to the Mental Health (Compulsory Assessment and Treatment) Act","author":"Bailey","year":"1992"},{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1192\/pb.28.1.12","article-title":"Risperidone long-acting injection: the first 50 patients","volume":"28","author":"Paton","year":"2004","journal-title":"Psychiatric Bulletin"},{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1017\/S1461145705006309","article-title":"Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome","volume":"9","author":"Taylor","year":"2006","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB21|cit21","volume-title":"Re-audit of the Use of Risperidone Long-acting Injection (RLAI): Financial Year 05\/06 & a Comparison with the Previous Year","author":"Young","year":"2007"},{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2753.2008.01032.x","article-title":"Impact of audit and feedback on antipsychotic prescribing in schizophrenia","volume":"15","author":"Wheeler","year":"2009","journal-title":"Evaluation in Clinical Practice"},{"key":"10.1111\/j.1365-2710.2010.01219.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2753.2008.01084.x","article-title":"Explicit versus implicit review to explore combination antipsychotic prescribing","volume":"15","author":"Wheeler","year":"2009","journal-title":"Journal of Evaluation in Clinical Practice"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2710.2010.01219.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2710.2010.01219.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:03:58Z","timestamp":1671818638000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2710.2010.01219.x"}},"subtitle":["Review of RLAI prescribing"],"short-title":[],"issued":{"date-parts":[[2010,11,5]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2710.2010.01219.x","relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11,5]]}}}